Unlike previous, studies that deemed PD-L1 expression to be a predictor for the evaluation of tumor efficacy post-immunotherapy [17], the predictive role of this parameter might be overturned upon sintilimab administration on patients with NSCLC. The gene discussed is CD274; the disease is neoplasm.